An interventional study of Exercise Training in Gastric Cancer, sponsored by University of Maia. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-12.
Sponsored by University of Maia · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Stomach Neoplasms with a site in Portugal — 6 open to participants now, 11 under way, 4 of them phase 3. Stomach Neoplasms · Portugal.
Among the 41 studies in Stomach Neoplasms with a site in Portugal, this one is the 29th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2022, is one of 5 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 36th registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →6 of the 41 studies in Stomach Neoplasms with a site in Portugal are open now. Recruiting first, the newest first:
Unidade Local de Saúde do Alto Ave, EPE · Sites in Portugal
Ages 18+
Daiichi Sankyo · Sites in Portugal, United States, Argentina and 23 more countries
Ages 18+
Hospital Beatriz Ângelo · Sites in Portugal
Ages 40–80
Instituto Portugues de Oncologia, Francisco Gentil, Porto · Sites in Portugal
Ages 45+
Unidade Local de Saúde Santa Maria · Sites in Portugal
Ages 18+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 16
First in 1999; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.
Median enrollment 296 across the 31 interventional studies, 325 across the 10 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 41 have an industry lead sponsor. The 10 most frequent:
University of Maia is the lead sponsor of 21 studies on the registry; 13 are open to participants now.
University of Maia has 1 study filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Stomach Neoplasms with a site in Portugal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04613570Instituto Portugues de Oncologia, Francisco Gentil, PortoSUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up | 2026-12-31 |
| NCT07920068Unidade Local de Saúde do Alto Ave, EPEEpinephrine 1:100,000 Versus 1:500,000 During Gastric Endoscopic Submucosal Dissection | 2027-02-27 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies in Stomach Neoplasms with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT4) is the standard perioperative treatment for resectable and advanced gastric adenocarcinoma. Although the FLOT4 regimen have shown increases in the overall survival, response rate, and progression-free survival, it is also associated with substantial toxicities. Prehabilitation is an effective strategy to improve physical fitness in cancer patients and reverse functional limitations and inadequate levels of physical activity that are associated with worse postoperative outcomes and treatment response. Therefore, the main objective of this study is to evaluate the effects of an online, supervised exercise-based prehabilitation program on the cardiorespiratory fitness level, functional fitness and quality of life among adults with gastric cancer undergoing neoadjuvant chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group will participate in a supervised online exercise prehabilitation program that will extend throughout the chemotherapy until one week before the scheduled surgery. The exercise program will consist of three sessions per week, each lasting 60 minutes. The design of the prehabilitation program is based on exercise prescription recommendations for cancer survivors and will be tailored to each patient's initial functional capacity. The exercise sessions will be conducted at home through an online platform, enabling real-time interaction among groups of patients.
Behavioral: Exercise Training
Participants from the control group will be offered optimal medical care, which includes general advice about healthy lifestyle including regular physical activity participation according to the current guidelines.
The exercise program will consist of three sessions per week, each lasting 60 minutes. The aerobic exercise will gradually increase the duration throughout the program to 40 minutes and exercise intensity from 30% to 59% of heart rate reserve. The resistance training will include bodyweight functional exercises and resistance exercises using elastic bands. The intensity of resistance exercise will progressively increase according to levels of progressive length and resistance of the elastic bands. The volume of resistance training will start with one set of 8 repetions. It will then gradually increase alongside the program to 2 sets of 12 repetitions. Participants will also be guided to assess their subjective effort using the Borg scale (RPE 12-15).
Aerobic capacity
Incremental Shuttle Walk Test (ISWT)
Time frame: Change from baseline to 1 week before surgery
Aerobic capacity
Incremental Shuttle Walk Test (ISWT)
Time frame: Change from 1 week before surgery to 30 days post-surgery
Aerobic capacity
Incremental Shuttle Walk Test (ISWT)
Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment
Muscle strength
Digital hand dynamometer
Time frame: Change from baseline to 1 week before surgery
Muscle strength
Digital hand dynamometer
Time frame: Change from 1 week before surgery to 30 days post-surgery
Muscle strength
Digital hand dynamometer
Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment
Body composition
Bioelectrical impedance
Time frame: Change from baseline to 1 week before surgery
Body composition
Bioelectrical impedance
Time frame: Change from 1 week before surgery to 30 days post-surgery
Body composition
Bioelectrical impedance
Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment
Health-related quality of life
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The final scores will range from 0 to 100, with higher scores on the functional scales representing a high level of functioning and higher scores on the symptom scales implying a stronger symptom burden.
Time frame: Change from baseline to 1 week before surgery
Health-related quality of life
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The final scores will range from 0 to 100, with higher scores on the functional scales representing a high level of functioning and higher scores on the symptom scales implying a stronger symptom burden.
Time frame: Change from 1 week before surgery to 30 days post-surgery
Health-related quality of life
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The final scores will range from 0 to 100, with higher scores on the functional scales representing a high level of functioning and higher scores on the symptom scales implying a stronger symptom burden.
Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment
Gastric cancer specific health-related quality of life
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC QLQ-STO22). The final scores will range from 0 to 100, with higher scores indicating worse symptomatic problems.
Time frame: Change from baseline to 1 week before surgery
Gastric cancer specific health-related quality of life
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC QLQ-STO22). The final scores will range from 0 to 100, with higher scores indicating worse symptomatic problems.
Time frame: Change from1 week before surgery to 30 days post-surgery
Gastric cancer specific health-related quality of life
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC QLQ-STO22). The final scores will range from 0 to 100, with higher scores indicating worse symptomatic problems.
Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment
Physical activity
Accelerometer (wGT3X, ActiGraph LLC, Pensacola, FL, USA)
Time frame: Change from baseline to 1 week before surgery
Physical activity
Accelerometer (wGT3X, ActiGraph LLC, Pensacola, FL, USA)
Time frame: Change from 1 week before surgery to 30 days post-surgery
Physical activity
Accelerometer (wGT3X, ActiGraph LLC, Pensacola, FL, USA)
Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment
Calf circumference
Time frame: Change from baseline to 1 week before surgery
Calf circumference
Time frame: Change from 1 week before surgery to 30 days post-surgery
Calf circumference
Time frame: Change from 30 days post-surgery to 15 days after the conclusion of curative treatment
Postoperative morbidity outcomes
Clavien-Dindo classification
Time frame: Within 30 days after surgery
Treatment compliance
Relative dose intensity, calculated as the ratio of the delivered dose intensity to the standard dose intensity
Time frame: Through chemotherapy completion
Adverse events
Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Time frame: During the treatment (neoadjuvant chemotherapy)
Number of hospitalizations
Time frame: Within 30 days after surgery
Length of hospital stay
Time frame: Within 30 days after surgery
Plan to share: Yes
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Jul 2025, 40 months after the start.
Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 40 months is above that.
Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Maia